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Abstract
Histone deacetylase inhibitors (HDACi) sensitize homologous recombination (HR)-proficient human ovarian cancer cells to
PARP inhibitors (PARPi). To investigate mechanisms of anti-tumor effects of combined HDACi/PARPi treatment we performed
transcriptome analysis in HR- proficient human ovarian cancer cells and tested drug effects in established immunocompetent mouse
ovarian cancer models. Human SKOV-3 cells were treated with vehicle (Con), olaparib (Ola), panobinostat (Pano) or Pano+Ola and
RNA-seq analysis performed. DESeq2 identified differentially expressed HR repair and immune transcripts. Luciferised syngeneic
mouse ovarian cancer cells (ID8-luc) were treated with the HDACi panobinostat alone or combined with olaparib and effects on
cell viability, apoptosis, DNA damage and HR efficiency determined. C57BL/6 mice with intraperitoneally injected ID8-luc cells
were treated with panobinostat and/or olaparib followed by assessment of tumor burden, markers of cell proliferation, apoptosis and
DNA damage, tumor-infiltrating T cells and macrophages, and other immune cell populations in ascites fluid. There was a significant
reduction in expression of 20/37 HR pathway genes by Pano+Ola, with immune and inflammatory-related pathways also significantly
enriched by the combination. In ID8 cells, Pano+Ola decreased cell viability, HR repair, and enhanced DNA damage. Pano+Ola
also co-operatively reduced tumor burden and proliferation, increased tumor apoptosis and DNA damage, enhanced infiltration of
CD8+ T cells into tumors, and decreased expression of M2-like macrophage markers. In conclusion, panobinostat in combination
with olaparib targets ovarian tumors through both direct cytotoxic and indirect immune-modulating effects.
Neoplasia (2022) 24, 63–75
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Epithelial ovarian cancer is the deadliest gynecologic cancer [1].
Approximately 60% of women are diagnosed with advanced stage III/IV
disease, characterized by peritoneal metastases and ascites. Poly ADP
ribose polymerase inhibitors (PARPi) have shown remarkable promise as
single agents in treating advanced stage BRCA1/2 mutant homologous
recombination (HR)-deficient ovarian cancer[2–9]. However, effective
treatment options for women with advanced stage HR-proficient ovarian
cancers remains an unmet need. Approximately half of all women diagnosed
with ovarian cancer are diagnosed with HR-proficient disease, including a
subset with CCNE1 amplified/gain with poor clinical outcomes [10–12].
We found that combination treatment with histone deacetylase inhibitors
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(HDACi) synergize with PARPi in HR proficient ovarian cancer, in part
through downregulation of HR repair [13–20].
Peritoneal metastases and ascites associated with advanced state
ovarian cancer involves complex interactions between ovarian tumor
cells and host inflammatory cells, including tumor promoting peritoneal
macrophages [21,22]. Our group and others have shown that protumorigenic macrophages, which are abundant in ovarian cancer ascites,
can be “re-educated” toward an anti-tumorigenic phenotype for therapeutic
benefit [22–24]. Both PARPi and HDACi are known to alter function of
specific immune cell types in the tumor microenvironment to promote antitumor immunity [25–30]. However, the combined effects of HDACi and
PARPi on peritoneal metastases and ascites in ovarian cancer are not known.
The purpose of this study was to elucidate the combined effects of HDACi
and PARPi in ovarian cancer. We hypothesized that HDACi sensitize ovarian
tumors to PARPi through downregulation of HR genes and alterations in
immune gene transcripts and functions. We performed whole transcriptome
sequencing in HR proficient SKOV-3 human epithelial ovarian cancer
cells treated with the HDACi panobinostat and the PARPi olaparib, and
confirmed that panobinostat causes significant downregulation of HR genes.
We also discovered that both panobinostat and olaparib cause alterations in
immune and inflammatory-related genes. The combination of panobinostat
and olaparib was tested in ID8-luc cells, a syngeneic mouse model of HRproficient epithelial ovarian cancer. We validated that the combination of
panobinostat and olaparib is synergistic in reducing cell viability in cultured
mouse epithelial ovarian cancer cells. As expected, panobinostat reduced HR
gene expression and function. Further, panobinostat and olaparib reduced
peritoneal metastases and tumor burden in a syngeneic mouse model of
ovarian cancer. Peritoneal macrophages derived from ascites after treatment
with panobinostat and olaparib showed a shift towards an anti-tumor
phenotype. As a result, this study provides new insight into dual mechanisms
of HDACi combined with PARPi that can be used to inform our ongoing
clinical trial (https://clinicaltrials.gov/ct2/show/NCT03924245) and future
immunotherapy combinations for women diagnosed with HR-proficient
ovarian cancer.

Materials and methods
Cell culture
SKOV-3 cell line was obtained from American Type Cell Culture
(ATCC). Mouse ID8 epithelial ovarian cancer cell lines expressing a
constitutive luciferase reporter plasmid (ID8-Luc) were obtained from Dr.
Frances Balkwill (Barts Cancer Institute, Queen Mary University of London)
[24]. The cell lines were maintained in culture as previously described
[19,23,31]. All cell lines used tested negative for mycoplasma.

Drugs and reagents
Panobinostat and olaparib were purchased from Selleck Chemicals
(Houston, TX). Both drugs were reconstituted to prepare 100 mM stock
solution using DMSO. Cell culture media was used to prepare further
dilutions as described below.
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described below. For all other in vitro experiments using ID8-luc cells, the
cells were treated with vehicle, 25 nM panobinostat alone, 10 μM olaparib
alone, 25 nM panobinostat and 10 μM olaparib for 24 h. The concentration
of DMSO added to cells was equalized among all treatment groups.

RNA-seq analysis
For transcriptome analysis, human SKOV-3 ovarian cancer cells were
treated with vehicle only (0.01% DMSO diluted in media) in the control
group (Con), 25 nM panobinostat alone (Pano), 10 μM olaparib alone (Ola)
and combined 25 nM panobinostat and 10 μM olaparib (Pano+Ola) for 8 h.
Three independent passages of cells were treated and assayed by RNA-seq
in the Vanderbilt Technologies for Advanced Genomics Core (VANTAGE)
core using the Illumina HiSeq2500 platform. RNA-seq reads were aligned
to the human genome hg19 using TopHat2 [32] and the number of reads
mapped to each gene was calculated by HTseq (http://www-huber.embl.de/
users/anders/HTSeq/). Differentially expressed genes between drug treatment
groups were detected by DESeq2 [33]. The P values were corrected for
multiple testing using the Benjamini-Hochberg procedure. The significantly
changed genes were determined based on fold change greater than 1.5
(FC>1.5) and the corrected P value less than 0.01 (FDR<0.01). Functional
enrichment analysis on differentially expressed genes to infer pathways and
regulatory mechanisms associated with drug treatments was performed by
WebGestalt (Web-based gene set analysis toolkit; http://bioinfo.vanderbilt.
edu/webgestalt/) [34]. Enrichment p-values were generated by the Fisher’s
exact test and adjusted by the Benjamini-Hochberg’s multiple test correction.
RNA-seq data files will be made publicly available at the GenBank repository
(BioProject Accession PRJNA767427).

Quantitative real time RT-PCR (qRT-PCR)
Using parallel RNA samples, we performed qRT-PCR analysis to measure
steady-state mRNA levels of selected HR and immune and inflammationrelated genes as validation of the drug-induced changes detected in our RNAseq experiments in SKOV-3 cells. We also used qRT-PCR analysis to validate
changes in expression of a subset of genes in ID8-luc cells treated with the
same drug concentrations and time points as described above. RNA isolation
and cDNA synthesis was performed as previously described [23]. Levels of
mRNA expression of selected HR-related and immune and inflammationrelated genes were quantified using human Taqman probes (ThermoFisher
Scientific, Waltham, MA) as described [35]. A list of probes used in our
human and mouse ovarian cancer cell lines including GAPDH as internal
control is shown in Supplemental Table 2. We also used Taqman qRT-PCR
analysis to measure mRNA expression of validated markers in the cellular
component of mouse ascites fluid [23].: the epithelial marker CK18 to
measure tumor cell content; the macrophage marker F4/80; a mediator of
cytotoxic T cell responses, CXCL9; the angiogenesis factor VEGFA; the M1
macrophage markers CCL3 and iNOS, and the M2 markers arginase-1 and
mannose receptor (see Supplemental Table 3 for probe information) [23].
For both sets of analysis, we determined expression using the  CT method
relative to corresponding GAPDH levels.

Panobinostat / olaparib treatment of cell lines
For cell viability studies in ID8-luc cells, we tested effects of 1, 2.5, 5,
10 and 20 nM panobinostat (Pano) and 2, 5, 10, 20, and 40 μM olaparib
(Ola) either as single drugs or as combined treatment (Pano+Ola) for 72 h.
The control (Con) group was treated with vehicle only (0.01% DMSO
diluted in media). For transcriptome analysis, ID8-luc cells were treated with
vehicle only, 25 nM panobinostat alone, 10 μM olaparib alone or 25 nM
panobinostat and 10 μM olaparib for 8 h to parallel our SKOV-3 experiments

Cell viability assay
500 ID8-luc cells were plated in 384 well plates, in triplicates and
treated as described above. Sulforhodamine B (SRB) assay was carried out
as described [18] and Combination Index determined using CompuSyn
software following Chou-Talay’s method [36] to assess interactions between
the panobinostat/olaparib combinations.
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Homologous recombination functional assays
Plasmid-based DNA repair assay
For measuring drug effects on homologous recombination (HR)
efficiency, the HR reporter plasmid pDRGFP and endonuclease encoding
pCBASce1 (I-Sce1) (both gifts from Maria Jasin; Addgene plasmids #26475
and #26477, respectively) [37,38] were used. ID8-luc cells grown on
glass coverslips were transfected with the plasmids using Lipofectamine
2000 according to manufacturer’s instructions (Thermo Fisher Scientific,
Waltham, MA), and then treated with vehicle, panobinostat, olaparib or
panobinostat/olaparib for 24 h as described above and visualized for GFP
expression using fluorescence microscopy as previously described [39].
Measurement of RAD51 and BRCA1 repair foci
ID8-luc cells grown on glass coverslips were pretreated for 6 h with the
known inducer of double-strand DNA breaks, cisplatin (0.5 μM; SigmaAldrich). The cells were then washed with PBS, and treated with vehicle,
panobinostat, olaparib or panobinostat/olaparib for 24 h as described above.
Following cessation of drug treatment, the cells were fixed, stained with
mouse monoclonal anti-BRCA1 (1:100 MilliporeSigma, Burlington, MA) or
rabbit polyclonal anti-RAD51 (1:100 MilliporeSigma), with acquisition and
analysis of fluorescent images as previously described [39].

A.J. Wilson et al.

65

baseline bioluminescence imaging (BLI) as previously described [40] and
randomized into 4 groups (n = 5) to ensure equivalent baseline tumor burden
before the start of drug treatment. Mice in the following treatment groups
were treated for 4 weeks: Vehicle (1% DMSO in PBS five times weekly IP
and PO); Panobinostat (2.5 mg/kg five times weekly IP, 1% DMSO in PBS
five times weekly PO; Olaparib (olaparib 100 mg/kg five times weekly PO
& 1% DMSO in PBS five times weekly IP); and Panobinostat±olaparib
(panobinostat 2.5 mg/kg five times weekly IP, olaparib 100 mg/kg five times
weekly PO). Animals were examined visually biweekly for the effects of tumor
burden and tumor growth, including weekly weight measurements and body
condition scoring throughout the duration of drug treatment. Pre-euthanasia
BLI was measured to determine tumor burden. Mice were euthanized by
carbon dioxide inhalation and secondary cervical dislocation according to
IACUC-approved protocols.
Following sacrifice, omental tumor implants were harvested, weighed
and snap-frozen, or fixed in 10% neutral-buffered formalin for 24 h for
immunostaining as described below. Ascites was collected by withdrawing
fluid from the peritoneal cavity with a hypodermic syringe, and the volume
measured. If no measurable ascites was present, peritoneal lavage was
performed by injecting 10 ml PBS IP and carefully extracting the fluid with a
hypodermic syringe. The cellular content of ascites fluids or peritoneal lavages
was isolated as previously described [23] and snap-frozen for RNA extraction
for qRT-PCR analysis.

High-content fluorescent microscopy
Following treatment of ID8-luc cells with vehicle, panobinostat, olaparib
or panobinostat/olaparib for 24 h, we performed high-content IF imaging of
cells using the ImageXpress Micro XL imaging platform (Molecular Devices
(Sunnyvale, CA). Images of cells stained with DAPI (Sigma) to mark cell
nuclei and were acquired in nine fields of view per well. Analysis of adherent
cell number and the cell cycle indices %G0 /G1 , %S and %G2 /M were
performed using MetaXpress software as previously described [39].

Western blot
For ID8-luc cells treated with vehicle, panobinostat, olaparib or
panobinostat/olaparib for 24 h as described above, whole cell protein
isolation, hydrochloric acid extraction of histones, western blotting and
signal detection were performed as previously described [15,39]. Antibodies
used were: rabbit polyclonal anti-cleaved PARP (1:1000 Cell Signaling
Technology, Danvers, MA) to assess apoptosis, mouse monoclonal antiγ H2AX (Ser139) (1:1000 MilliporeSigma) to assess DNA damage, mouse
monoclonal anti-β-actin (1:10,000 Sigma-Aldrich) as a loading control
for whole cell extracts and mouse monoclonal anti-histone H3 (1:1000
MilliporeSigma) as a loading control for histone extracts.

Animal studies
Six to eight-week-old C57BL/6 female mice were used for these
studies. All mice were maintained and handled at Vanderbilt University
as per respective Institutional Animal Use and Care Committee (IACUC)
guidelines. Experiments were conducted in accordance with American
Association for Laboratory Animal Science (AALAS) and ARRIVE
guidelines. Mice were group housed (maximum 5 mice/cage) with standard
bedding and ad libitum access to food and water. Animal rooms were
maintained at constant temperature and humidity with a 12 h light/dark
cycle.
Panobinostat and olaparib treatment of mice
All experimental C57BL/6 mice used were bred in the colony of Dr.
Fiona Yull at Vanderbilt. Mice were injected intraperitoneally with 5 × 106
ID8-luc cells as previously described [23]. After 30 days, mice underwent

Immunostaining of tumor sections
Tissue fixation, processing and sectioning methods of harvested
ID8-luc xenografts were performed as previously described [18,23]. In
ID8-luc tumors, immunohistochemistry (IHC) for mib-1/Ki67 (1:1000;
rabbit polyclonal anti-mib-1/Ki67, Vector Laboratories, Burlingame, CA),
cleaved caspase-3 (1:300; rabbit polyclonal anti- cleaved caspase-3, Cell
Signaling Technology, Danvers, MA), and γ H2AX (Ser139) (1:100; mouse
monoclonal MilliporeSigma) were performed as previously described [16].
Fluorescent-IHC image acquisition and analysis of co-staining for the panmacrophage marker F4/80 (1:200 rat polyclonal anti-mouse F4/80, AbD
Serotec, Oxford, UK), and the M2 macrophage marker arginase-1 (1:200;
rabbit polyclonal anti-arginase-1, GeneTex, Irvine, CA), and separately for
the cytotoxic T cell marker CD8 (1:100; rat monoclonal anti-mouse CD8,
Novus Biologicals, Centennial, CO), was performed as previously described
[23]. Cell nuclei were identified by staining with DAPI (Sigma-Aldrich). At
least 1000 cells were counted in at least 5 independent fields under high power
(x40) for these counts.

Statistical analysis
Statistical analyses were performed using GraphPad Prism, Version 8
(La Jolla, California, USA). Comparisons of group means in cultured cells
were performed by 2-tailed Student’s t test. For mouse experiments, group
means were compared by 2-tailed Mann-Whitney test. A p-value <0.05 was
considered statistically significant.

Results
Transcriptome sequencing reveals dual regulation of HR repair and
immune gene transcripts in cells treated with panobinostat and olaparib
We have previously shown that HDACi such as SAHA, entinostat
and panobinostat downregulate expression of selected HR genes in HRproficient human ovarian cancer cells [18–20]. To identify genome-wide
alterations associated with HDACi and PARPi combination treatment,
we performed whole transcriptome sequencing of SKOV-3 cells using the
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Fig. 1. Coordinated downregulation of homologous recombination gene transcripts and modulation of immune gene transcripts in cells treated with
panobinostat and olaparib in SKOV-3 cells. SKOV-3 cells were treated with vehicle (0.01% DMSO), panobinostat (25 nM), olaparib (10 μM) or the
combination for 8 h. Heat map of drug effects on expression of (A) a panel of 37 HR-related genes and (B) immune and inflammation-related genes by
RNA-seq. Differentially expressed genes were detected using DESeq2 (Fold change>1.5 and FDR<0.05). Parallel Taqman qRT-PCR validation of selected
(C) HR genes and (D) immunity-related genes normalized for corresponding GAPDH levels. Values are mean+SEM expressed relative to control treatment;
∗
p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to
panobinostat alone; Student’s t test (For interpretation of the references to color in this figure, the reader is referred to the web version of this article.).
Illumina HiSeq2500 platform. We extracted RNA after treatment with
10 μM olaparib, 25 nM panobinostat, or the combination of 10 μM olaparib
and 25 nM panobinostat for 8 hr. Robust changes in transcript expression
were found compared to control in cells treated with olaparib (2929 up, 90
down), panobinostat (6477 up, 3078 down), and the combination (5985 up,
2958 down) using a criterion of FDR<0.05, >1.5 fold increase or decrease
in expression (Supplemental Fig. 1). As expected, panobinostat treatment,
alone and combined with olaparib, led to coordinated downregulation of HR
machinery transcripts such as RAD21, RAD51D, RAD51, FANCD2, WEE1,
and RPA1/2 (black boxes) (Fig. 1A). Downregulation of HR transcripts were
validated using qRT-PCR, and gene expression levels of BRCA1, BRCA2,
RAD51, RAD54B and WEE1 were significantly downregulated in both the
panobinostat and the combination treatment groups (Fig. 1C). There was no
significant change in HR genes in cells treated with olaparib alone, with the
exception of RAD52 which showed a significant upregulation (FDR<0.05,
1.7 fold increase) by RNA-seq analysis (blue box).
Next, we performed functional enrichment analysis using Geneset
ontology (WebGestalt). In the cells treated with the panobinostat and
olaparib combination, there was enrichment in gene alterations associated
with immune and inflammation response pathways (Supplementary Table

1, FDR< 0.05). Genes associated with tumor immunity were both
upregulated (grey) or downregulated (black) (Fig. 1B). We validated the
expression of immune regulatory transcripts by qRT-PCR, and confirmed
that panobinostat alone and in combination with olaparib (green bars)
showed a significant upregulation in IL8, NFKBIZ, CXCL3, and CD274
transcripts compared to vehicle or olaparib treatment (Fig. ID). Whereas,
TYRO3 and ZBTB1 transcripts were both significantly downregulated in the
panobinostat and combination treatment groups (Fig. 1D).

Panobinostat decreases HR gene expression and function and synergizes
with olaparib in ID8-luc HR proficient mouse epithelial ovarian cancer
cells
Having identified modulation of multiple HR, immune and
inflammation-related genes by the panobinostat/olaparib combination
in SKOV-3 cells, we then tested drug effects in a stable luciferised clone of
the ID8 mouse ovarian cancer cell line (ID8-luc). We have experience with
multiple intraperitoneal ovarian cancer models in immunocompetent mice,
including the ID8-luc model [21,23]. We first validated that drug treatment
of ID8-luc cells induced similar changes in expression of a subset of HR and
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Fig. 2. Panobinostat alone and combined with olaparib reduces HR proficiency in ID8-luc cells. HR repair efficiency of DNA double-strand breaks in drugtreated ID8-luc cells was measured in three assays. Cells were pre-treated with 0.5μM cisplatin for 6 h were then treated with panobinostat (25 nM), olaparib
(10 μM) or the combination for a further 24 h, and formation of BRCA1 (A&B) and RAD51 foci (C&D) analyzed by IF. Representative BRCA1 and RAD51
images (green) are shown; DAPI-stained nuclei are in blue. (E&F) IF analysis of GFP expression in ID8-luc cells co-transfected with the pDRGFP and I-Sce1
plasmids (both 1 μg). Cells were then treated with panobinostat (25 nM), olaparib (10 μM) or the combination for 24 h. At least 100 cells were counted
(x40) for each treatment in the three assays. Values are mean+SEM; ∗ p < 0.01 compared to control; a p < 0.01 relative to olaparib alone, Student’s t test (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
immunity-related genes as those observed in SKOV-3 cells (Supplemental
Fig. 2). To measure HR efficiency in ID8-luc cells, we pre-treated cells
with the DNA damaging drug 0.5 μM cisplatin for 6 h to induce double
strand breaks, and then treated cells with panobinostat, olaparib or the
combination for an additional 24 h. After cell fixation, we performed IF
staining for BRCA1 and RAD51. We counted cells with BRCA1 staining
and RAD51 foci and found significant reduction in panobinostat-treated

cells, with additional reduction in combination-treated cells (Fig. 2A–D).
In the second approach, we co-transfected ID8 cells with the pDRGFP and
I-Sce1 plasmids, and treated with cells as above (Fig. 2E&F). In panobinostat
treated cells, there was a significant reduction in cells expressing DRGFP.
Thus, the reduction in HR efficiency in ID8-luc cells is consistent with the
coordinated decrease in HR gene transcripts in SKOV-3 and ID8-luc cells
after panobinostat treatment, whether alone or combined with olaparib.
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Fig. 3. Panobinostat alone and combined with olaparib co-operatively reduces cell viability in ID8-luc cells. In ID8-luc cells treated with panobinostat (25 nM),
olaparib (10 μM) or the combination (24 h), DAPI-stained nuclei were analyzed by IF to measure (A) adherent cell number and percentage of cells in (B)
Go/G1 and (C) S phase of the cell cycle. (D) ID8-luc cells were treated with increasing concentrations of panobinostat and olaparib for 72 h, and cell viability
was measured using SRB assay. Combination Index (CI) for ED50 and ED75 was calculated by isobologram analysis. CI<1 is synergistic. ∗ p < 0.05 compared
to a CI of 1, Student’s t test. (E) Western blot analysis of expression of the apoptosis marker cleaved PARP in whole cell extracts and the DNA damage marker
γ H2AX in isolated histone extracts in ID8-luc cells treated as described in B. (F) Densitometry of western blots. Cleaved PARP and γ H2AX was measured
relative to corresponding actin and histone H3 expression, respectively, Values are mean+SEM; ∗ p < 0.01 compared to control; a p < 0.01 relative to olaparib
alone, b p < 0.01 relative to panobinostat alone, Student’s t test.
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Fig. 4. Panobinostat alone and combined with olaparib reduce tumor burden in ID8-luc-injected mice associated with reduced proliferation and increased
apoptosis and DNA damage. C57BL/6 mice were injected with 5 × 106 ID8-luc cells. 30 days after tumor cell injection, mice underwent bioluminescence
imaging (BLI) to establish baseline luminescence and then treated with vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times
weekly PO) and the panobinostat/olaparib combination for 4 weeks. Immediately before sacrifice, mice were re-imaged and solid tumor and ascites collected
at necropsy. (A) Change in bioluminescence from baseline. Representative images from BLI analysis are shown in (B). Values are mean±SEM of n = 5
per group. (C) Ascites volume at sacrifice. (D) Harvested omental tumor weight. In harvested tumors, the percentage of cells staining for (E) γ H2AX, (F)
cleaved caspase-3 and (G) Ki67. Values are mean±SEM for 3 independent experiments. At least 1000 cells were counted (40X) for each drug treatment per
experiment. ∗ p < 0.02 compared to vehicle; a p < 0.02 relative to SAHA alone; b p < 0.01 relative to olaparib alone, Mann-Whitney test. (H) High power
(x40) representative images of γ H2AX, cleaved caspase-3 and Ki67, staining for each drug treatment.
We then performed high content immunofluorescence (IF) to measure
treatment effects on cell number and cell cycle indices. Panobinostat, alone
and combined with olaparib, had a greater effect on reducing cell number
compared to olaparib alone, which is consistent with HR-proficient status
and relative resistance to olaparib (Fig. 3A). Panobinostat alone and combined
with olaparib significantly increased G0 /G1 and decreased the S phase fraction
(Fig. 3B&C). We also assessed drug effects on viability of ID8-luc cells
treated with increasing concentrations of panobinostat and/or olaparib for
72 h using SRB assays. As shown in Fig. 3D, panobinostat and olaparib
had relatively minimal effects on cell viability as single agents, but were
synergistic in combination. This was demonstrated by isobologram analysis
which showed a Combination Index (CI) value for ED50 and ED75 that
were significantly <1, indicative of synergism (p < 0.05, Student’s t test)
[15,16,19,36]. Finally, we showed that reduced HR repair efficiency in ID8luc cells by panobinostat + olaparib combination treatment was associated
with increased expression levels of the DNA damage marker, γ H2AX, and
increased expression of the apoptosis marker cleaved PARP, compared to
either drug alone (Fig. 3E&F).

The combination of panobinostat and olaparib reduces tumor burden in
a syngeneic model of ovarian cancer
Having confirmed similar co-operative anti-tumor effects of combining
HDACi and PARPi in ID8-luc cells than those observed in human ovarian
cancer cell lines [18–20], we tested our drug combination in C57BL/6 mice
injected intraperitoneally with 5 × 106 ID8-luc cells. Peritoneal metastases
were allowed to establish for 4 weeks, and mice were subsequently treated with
vehicle, panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg
5 times weekly PO) and the panobinostat/olaparib combination for 4
weeks after randomization. Noninvasive BLI measurements were obtained
at baseline and compared to the end of treatment (Fig. 4A, B). After sacrifice,

ascites solid tumors from peritoneal implants and omentum were collected
and measured (Fig. 4C&D). As expected, there was no significant difference
in tumor burden in olaparib-treated mice compared to controls. However,
panobinostat significantly reduced tumor burden as a single agent, and these
effects were potentiated by panobinostat+olaparib combination treatment.
All mice tolerated the treatments well and no significant toxicity or change in
weights were noted (Supplemental Fig. 3).
Tumor sections were stained for molecular markers for proliferation
(Ki67), apoptosis (cleaved caspase 3), and DNA damage (γ H2AX) (Fig. 4E–
H). Panobinostat treatment led to a significant decrease in Ki67 expression
and an increased expression of cleaved caspase 3 and γ H2AX compared to
vehicle, effects which were potentiated by its combination with olaparib.

Panobinostat and olaparib alter the immune phenotype in tumors and
ascites fluid
We have shown that targeting macrophages to alter functions from
an overall M2-like pro-tumor to an M1-like anti-tumor phenotype
can reduce tumor burden in ID8 syngeneic models of ovarian cancer
accompanied by increased tumor-infiltrating cytotoxic T cells [23]. To
evaluate drug effects on phenotype of tumor-infiltrating immune cells, we
first performed immunofluorescence analysis of tumor sections co-stained
for the pan-macrophage marker F4/80 and the M2 marker arginase-1
(Arg-1). Representative tumor sections stained for F4/80, Arg-1, CD8 and
cell nuclei (DAPI) are shown in Fig. 5A. As shown in Fig. 5B–D, the
panobinostat/olaparib combination results in significantly increased numbers
of F4/80-positive, Arg-1-negative tumor-infiltrating macrophages compared
to vehicle or either drug alone. Since M2-like tumor-associated macrophages
are known to induce immunosuppressive effects, especially limiting cytotoxic
T cell responses [21,41,42], we also stained tumors for CD8-positive T cells.
Treatment of mice with panobinostat/olaparib combination showed higher
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Fig. 5. Panobinostat alone and combined with olaparib increases macrophage recruitment, decreases M2 macrophages and increases CD8-positive T
cell infiltration in the tumor microenvironment. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle,
panobinostat (2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or the panobinostat + olaparib combination or 4 weeks. (A)
Representative images of tumors stained for F4/80 (green), Arg-1 (red), and DAPI (nuclei; blue). Separate staining for CD8 (red) is also shown. In harvested
tumors, (B) counts of the percentage of F4/80-positive macrophages per high-powered field (HPF), (C) percentage of arginase-1 (Arg-1) positive cells, (D)
the ratio of Arg-1 positive to F4/80 positive cells, and (E) the of CD8 positive cells. Counts were quantified from 5 representative HPF from each sample.
∗
p < 0.05 single drug effect relative to vehicle; a p < 0.01 combination drug effect relative to olaparib alone, b p < 0.01 combination drug effect relative to
panobinostat alone; Mann-Whitney test (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.).
numbers of tumor-infiltrating CD8-positive T cells above that of either drug
alone (Fig. 5E).
We have also shown that cell pellets from ascites predominantly contain
a mix of tumor cells and macrophages (>90% of the immune cells) [21,40].
Therefore, we performed qRT-PCR after RNA extraction from ascites cells.
Panobinostat decreased expression of CK18, an epithelial marker, consistent
with a decrease in tumor burden (Fig. 6A). These effects were potentiated in
combination with olaparib, F4/80 is a marker of macrophages, while CXCL9
promotes T cell recruitment and cytotoxic, anti-tumor responses [43]; both
increased by panobinostat and in the panobinostat + olaparib combination
(Fig. 6B&C). The expression levels of VEGFA, a marker of angiogenesis
secreted by tumor cells and macrophages into ascites fluid [21,44,45], was
also significantly reduced by panobinostat alone and in combination with
olaparib (Fig. 6D).

We also assessed expression levels of macrophage M1 and M2 markers
in ascites cells (Fig. 6E–H). Both panobinostat and olaparib increased the
expression of CCL3 (M1) and decreased expression of the mannose receptor
(M2). In contrast, panobinostat alone and combined with olaparib increased
the expression of iNOS (M1) and decreased the expression of arginase-1
(M2). These results, along with the cytotoxic T cell infiltration, suggest a
relative shift from a pro-tumorigenic to an anti-tumorigenic macrophage
phenotype that is driven primarily by panobinostat and potentiated by
olaparib.

Discussion
While PARPi are promising single agents in treating advanced stage
BRCA1/2 mutant homologous recombination (HR)-deficient ovarian cancer
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Fig. 6. Panobinostat reduces expression of tumor epithelial and M2 macrophage markers and increases expression of pan-macrophage and M1 markers in
ascites cells from ID8-luc-injected mice. C57BL/6 mice were injected with ID8-luc cells. 30 days after injection, mice were treated with vehicle, panobinostat
(2.5 mg/kg 5 times weekly PO), olaparib (100 mg/kg 5 times weekly PO) or panobinostat + olaparib combination for 4 weeks. After sacrifice, ascites was
harvested and mRNA extracted from the cell pellet. Drug effects on steady state mRNA expression of (A) epithelial marker CK18, (B) macrophage marker
F4/80, (C) T cell recruitment factor CXCL9, (D) angiogenic factor VEGFA, (E, F) M1 macrophage markers CCL3 and iNOS) and (G, H) M2 macrophage
markers, arginase-1 and mannose receptor were measured by qRT-PCR. Relative expression values are expressed as mean±SEM, calculated using the 2−Ct
method relative to corresponding GAPDH levels. ∗ p < 0.01 single drug effect relative to control; a p < 0.01 relative to olaparib alone; b p < 0.01 relative to
panobinostat alone, Mann-Whitney test.
[2–8], a persistent problem is the lack of effective treatment options for
women with advanced stage HR-proficient ovarian cancers. We have shown
that epigenetic drugs such as HDACi can sensitize HR-proficient ovarian
cancer cells to PARPi, at least in part through downregulation of HRrelated genes [18–20]. In this study, whole transcriptome sequencing in
HR proficient SKOV-3 human epithelial ovarian cancer cells confirmed that
there is coordinated downregulation of HR genes in cells treated with the
combination of the HDACi panobinostat and the PARPi olaparib. We also
discovered that both panobinostat and olaparib cause alterations in multiple
genes implicated in immune and inflammatory responses in these cells. This
motivated us to test the panobinostat + olaparib combination in the wellcharacterized ID8 syngeneic mouse ovarian cancer model to determine drug
effects on tumor development in the context of the full immune repertoire
[21,23,40,46].
Using luciferised ID8 cells (ID8-luc), we first established that
panobinostat + olaparib combination has similar anti-tumor effects as
previously observed in human ovarian cancer cell lines treated with HDACi
and PARPi [18–20]. The drug combination was synergistic in reducing cell
viability, and reduced efficiency of HR repair resulting in increased DNA
damage-induced apoptosis. Panobinostat and olaparib also co-operatively
decreased the overall tumor burden in C57BL/6 mice injected IP with

ID8-luc cells, reducing both solid tumors and accumulation of ascites fluid.
Consistent with the tumor burden data and our in vitro observations, the
combination also co-operatively reduced tumor proliferation and increased
DNA damage and apoptosis as observed in harvested tumors.
The panobinostat + olaparib combination also induced striking changes
in immune cells in the tumor microenvironment, with a strong shift
towards an anti-tumorigenic phenotype. Notably, panobinostat + olaparib
combination induced higher overall numbers of macrophages in both tumors
and in ascites fluid, based on expression of the pan macrophage marker F4/80.
Importantly, these recruited macrophages were less likely to have an M2like pro-tumorigenic phenotype, since we observed reduced overall numbers
and proportion of M2-like tumor-infiltrating macrophages, and increased
expression of M1 macrophages markers accompanied reduced expression of
M2 markers in the cellular content of ascites fluid. We also observed a cooperative increase in tumor-infiltrating cytotoxic T cells in mice treated with
panobinostat + olaparib combination, accompanied by increased levels of
CXCL9 in cells in ascites fluid. CXCL9 has recently been identified as a
critical mediator of anti-tumor T cell responses, and high CXCL9 levels are
associated with increased numbers of CD8 positive T cells in ascites and
better prognosis in ovarian cancer patients [43,47]. Graphical representation
of these findings is illustrated in Fig. 7.
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Fig. 7. Graphical abstract illustrating the mechanism of action of panobinostat in combination with olaparib.
The shift towards a less immunosuppressive tumor microenvironment
are consistent with studies showing that modulating the phenotype of
M2-like tumor-associated macrophages towards M1-like cytotoxic, proinflammatory functions is a promising therapeutic strategy [22,23,48].
We recently showed that specific activation of canonical NF-kappa B in
macrophages in tumor-bearing IKFM transgenic mice induces potent antitumorigenic effects, accompanied by increases in infiltration of M1 polarized
macrophages and cytotoxic T cells into tumors, and increased levels of
CXCL9 levels in ascites fluid [23]. Moreover, epigenetic drugs such as
HDACi are known to have immunomodulatory functions that increase
cytotoxic T cell functions [25–27]. A limitation of our current study is
that SKOV-3 cells and ID8 cells do not represent high grade serous ovarian
cancer (HGSOC) cells, but HR proficient ovarian cancer cells. However,
we have shown that entinostat, a class 1/2 specific HDACi in combination
with olaparib significantly improved survival in a patient-derived xenograft
(PDX) mouse model of HGSOC [20]. Further, ovarian cancer occurs mostly
in post-menopausal women, whereas mouse models used are 6–8-weekold representing the immune-landscape of younger women. To address this
caveat, age-appropriate HGSOC models, in particular those correlating with
post-menopausal women, will be used for detailed mechanistic explorations.
In addition, post-menopausal women have compromised immune functions.
To address this, studies segregating the relative effects of HR downregulation
and immune environment modulation will be carried out.

Conclusions
We have observed enhanced anti-tumorigenic effects of HDACi/PARPi
combinations in both immunocompromised and immunocompetent
mouse models [18–20]. This suggests that the rational combination of

panobinostat + olaparib targets ovarian tumors through both direct cytotoxic
and indirect immune-modulating effects. This study provides new insight
into mechanisms of HDACi combined with PARPi that can be used to
inform our current clinical trial testing the entinostat/olaparib combination
in women with HR-proficient tumors (NCT03924245) and to inform
epigenetic drug combinations using immunotherapy.
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